
肺血管阻力在评估肺动脉高压患者病情中的应用价值 - 中华心血管 …
研究发现PVR≥2 wood单位时已与肺血管疾病相关且患者生存率显著降低,PVR≥2 wood单位更适合在高危人群中早期诊断SSc-PAH。之前还有研究发现动态PVR可作为SSc-PAH的独立预测因子 [40] ,但其预测价值需要考虑疾病分类或
2022 ESC/ERS Guidelines for Pulmonary Hypertension: Key Points
2022年8月30日 · Pulmonary hypertension (PH) is now defined by a mean pulmonary arterial pressure >20 mm Hg at rest. The definition of pulmonary arterial hypertension (PAH) also implies a pulmonary vascular resistance (PVR) >2 Wood …
Physiology, Pulmonary Vascular Resistance - StatPearls - NCBI Bookshelf
2024年1月31日 · Increased pulmonary vascular resistance is the leading cause of pulmonary hypertension. Furthermore, increased PVR can lead to pulmonary hypertension, leading to increased PVR due to chronic vasoconstriction, vascular remodeling, endothelial thickening, arteriolar smooth muscle hypertrophy, and increased thromboxane and endothelin-1 production.
Pulmonary vascular resistance and clinical outcomes in patients …
Among patients with a mPAP of at least 19 mm Hg and pulmonary artery wedge pressure of 15 mm Hg or less, the adjusted hazard ratio (HR) for mortality was 1·71 (95% CI 1·59-1·84; p<0·0001) and for heart failure hospitalisation was 1·27 (1·13-1·43; p=0·0001), when comparing PVR of 2·2 Wood units or more to less than 2·2 Wood units.
Pulmonary vascular resistance index: Getting the units right …
Pulmonary vascular resistance (PVR) and PVR index (PVRI) are key variables in a broad range of contexts, including prediction of outcomes in heart and liver transplantation, determining candidacy for closure of atrial or ventricular septal defects, …
Clinical application of pulmonary vascular resistance in patients …
2021年10月20日 · As one of the diagnostic indicators of PAH hemodynamics, PVR plays an irreplaceable role in the diagnosis and clinical classification of precapillary pulmonary hypertension. At the same time, PVR and PAH risk stratification indicators have a certain correlation, and also have important value in the prognosis and early diagnosis of some PAH.
Future treatment paradigms in pulmonary arterial hypertension: …
2025年2月20日 · Pulmonary arterial hypertension (PAH), a condition characterised by progressive obliterative pulmonary vascular remodelling, is a chronic and life-threatening ailment despite advances in treatment. 1,2 Over the past three decades, PAH treatment has primarily targeted the endothelin, nitric oxide, and prostacyclin pathways. 3–5 These treatments have resulted in notable improvements in ...
Vascular Remodeling in Pulmonary Arterial Hypertension: The …
Clinically, it is important to distinguish pre-capillary PAH from post-capillary pulmonary hypertension. This can be determined by measuring the pulmonary arterial wedge pressure (PAWP) and PVR. PAH, also known as pre-capillary PH, is then defined by a mPAP ≥ 20 mmHg and a PAWP ≤ 15 mmHg.
Management of Pulmonary Arterial Hypertension: Current
2025年3月8日 · Primary pulmonary hypertension (PPH), now known as pulmonary arterial hypertension (PAH), has induced significant treatment breakthroughs in the past decade. Treatment has focused on improving patient survival and quality of life, and delaying disease progression. Current therapies are categorized based on targeting different pathways known to contribute to PAH, including endothelin receptor ...
Impact of BMPR2 mutation on the severity of pulmonary arterial ...
2025年2月28日 · As the disease progresses, pulmonary vascular remodeling increases PVR, a key feature of PAH. In the early stages, the heart compensates for rising mPAP and PVR to maintain CI and CO. However, as PVR exceeds the right ventricle’s capacity, it loses the ability to sustain normal CI and CO, signaling a decline in right heart function.